Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artivion ( (AORT) ) has shared an update.
On August 6, 2025, Artivion, Inc. announced the appointment of Lance A. Berry as Chief Operating Officer, effective August 11, 2025. Berry, who will continue his roles as Chief Financial Officer and Treasurer, brings extensive experience from his previous positions at Wright Medical Group N.V. and Arthur Andersen. His compensation package includes a base salary, cash incentives, and equity grants. Additionally, Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer, announced his retirement effective March 31, 2026. Stanton will continue to offer strategic advice and transition services for up to a year post-retirement.
The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
Artivion’s overall score is driven by strong technical momentum and positive earnings call guidance, highlighting growth potential. However, profitability challenges and valuation concerns temper the score.
To see Spark’s full report on AORT stock, click here.
More about Artivion
Average Trading Volume: 359,761
Technical Sentiment Signal: Buy
Current Market Cap: $1.75B
For detailed information about AORT stock, go to TipRanks’ Stock Analysis page.